TuisDSKYF ā¢ OTCMKTS
add
Daiichi Sankyo Co Ltd
Vorige sluiting
$31,10
Dagwisseling
$28,90 - $32,40
Jaarwisseling
$25,95 - $44,64
Markkapitalisasie
60,01Ā mjd USD
Gemiddelde volume
4,92Ā k
P/V-verhouding
-
Dividend-opbrengs
-
PrimĆŖre beurs
TYO
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(JPY) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 446,55Ā mjd | 18,92% |
Bedryfskoste | 254,60Ā mjd | 10,82% |
Netto inkomste | 61,29Ā mjd | 53,26% |
Netto winsgrens | 13,73 | 28,92% |
Wins per aandeel | ā | ā |
EBITDA | 110,60Ā mjd | 69,06% |
Effektiewe belastingkoers | 25,60% | ā |
Balansstaat
Totale bates
Totale aanspreeklikheid
(JPY) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 707,67Ā mjd | 19,79% |
Totale bates | 3,30Ā bn | 24,46% |
Totale aanspreeklikheid | 1,67Ā bn | 58,69% |
Totale ekwiteit | 1,62Ā bn | ā |
Uitstaande aandele | 1,90Ā mjd | ā |
Prys om te bespreek | 0,04 | ā |
Opbrengs op bates | 6,97% | ā |
Opbrengs op kapitaal | 13,24% | ā |
Kontantvloei
Netto kontantverandering
(JPY) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 61,29Ā mjd | 53,26% |
Kontant van bedrywe | 33,49Ā mjd | 284,55% |
Kontant van beleggings | -10,87Ā mjd | -108,72% |
Kontant van finansiering | -78,62Ā mjd | -75,67% |
Netto kontantverandering | -97,59Ā mjd | -237,26% |
Beskikbare kontantvloei | 53,27Ā mjd | -46,31% |
Meer oor
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
HUB
Gestig
28 Sep. 2005
Hoofkwartier
Webwerf
Werknemers
18Ā 726